EU to receive 100 million additional doses of COVID-19 vaccine Comirnaty
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) late yesterday announced they will supply an additional 100 million doses of Comirnaty (BNT162b2), the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021, with the news edging the German biotech firm’s shares up more than 3% to $91.00 in pre-market trading today.
This announcement is a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its Advanced Purchase Agreement signed on November 11. This agreement brings the total number of doses to be delivered to the EU to 300 million.
Pfizer chairman and chief executive Albert Bourla commented: “We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to spread at an alarming rate. In partnership with the European Commission, member states and healthcare providers, we will be able to reach a total of 150 million Europeans across the continent.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze